Showing 7261-7270 of 8880 results for "".
- Cetaphil Brand Revamps RestoraDerm Product Linehttps://practicaldermatology.com/news/20141117-cetaphil_brand_revamps_restoraderm_product_line/2459061/Galderma Laboratories, LP unveiled a new and improved look for their Cetaphil RestoraDerm product line. The new look brings eczema to the forefront of the packaging featuring their new names, Cetaphil RestoraDerm Eczema Calming Body Wash and Cetaphil RestoraDerm Eczema Calming M
- Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenuehttps://practicaldermatology.com/news/20141117-actavis_to_acquire_allergan_to_create_top_10_global_growth_pharmaceutical_company_with_23_billion_in_revenue/2459062/Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock. Based on the closing price of A
- CMS Assigns Q-code to Fish Skin Technology, Kerecis Reportshttps://practicaldermatology.com/news/20141113-cms_assigns_q-code_to_fish_skin_technology_kerecis_reports/2459065/The new Omega3 tissue-regeneration material from Kerecis Limited—dubbed fish skin—has received a "Q" code from the Centers for Medicare and Medicaid Services (CMS). Kerecis Omega3 Wound, indicated for the management of chronic wounds including diabetic, vascular and other hard-to-heal wounds, has b
- Foamix Receives USPTO Patents for Topical Tetracyclineshttps://practicaldermatology.com/news/20141113-foamix_receives_uspto_patents_for_topical_tetracyclines/2459066/Foamix Pharmaceuticals Ltd., a clinical-stage, specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that the United States Patent and Trademark Office ("USPTO") has recently issued to it two additi
- Oculus Innovative Sciences Commercializes Microcyn-Based Solution and Hydrogel for Treatment of Mild-to-Moderate Acne in Europehttps://practicaldermatology.com/news/20141113-oculus_innovative_sciences_commercializes_microcyn-based____solution_and_hydrogel_for_treatment_of_mild-to-moderate_acne_in_europe/2459068/Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in 37 countries, today announced the European commercialization of Microcyn(R)-based GramaDerm(TM) Solution a
- Brodalumab Outperforms Ustekinumab in Head-to-Head Trialhttps://practicaldermatology.com/news/20141112-brodalumab_outperforms_ustekinumab_in_head-to-head_trial/2459070/New findings from the Phase III AMAGINE-3 trial suggest that the investigational IL-17 inhibitor brodalumab (Amgen/AstraZeneca) may be superior to ustekinumab in treating patients with moderate to severe psoriasis. In the study, investigators evaluated more than 1,800 patients who were randomized to
- Dr. Mary Lupo Joins Aquavit Pharmaceuticals' Scientific Advisory Boardhttps://practicaldermatology.com/news/20141106-dr_mary_lupo_joins_aquavit_pharmaceuticals_scientific_advisory_board/2459072/Mary Lupo, MD, FAAD has joined the US Scientific Advisory Board of Aquavit Pharmaceuticals. Dr. Lupo is a board-certified dermatologist who is internationally recognized for non-surgical skin rejuvenation. In 1984, she opened
- Promius Pharma Launches Promiseb Topical Cream 60 Gram Optionhttps://practicaldermatology.com/news/20141105-promius_pharma_launches_promiseb_topical_cream_60_gram_option/2459073/Promius Pharma LLC launched Promiseb Topical Cream in a new 60 gram box. This well-regarded non-steroidal cream for the treatment of seborrheic
- A Pivotal Phase III Gevokizumab Study is Initiated in Patients With Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20141104-a_pivotal_phase_3_gevokizumab_study_is_initiated_in_patients_with_pyoderma_gangrenosum/2459074/The Phase III gevokizumab study in patients with active pyoderma gangrenosum, a rare neutrophilic dermatosis of expanding necrotic skin ulcers, is open for patient enrollment. The objective of the study is to assess the efficacy and safety of gevokizumab in treating the active ulc
- AmSpa Welcomes Cathy Christensen as Executive Director or Operations and Communicationshttps://practicaldermatology.com/news/20141009-amspa_welcomes_cathy_christensen_as_executive_director_or_operations_and_communications/2459089/Cathy Christensen, former editor of Skin Inc. magazine and conference director for the Face and Body events, is now Executive Director or Operations and Communications of AmpSpa. Christensen said, "I have been honored to have a role in serving the professional skin care industry's profes